The Company


The needs addressed by PROCOMCURE are the dearth of novel antibacterial agents and want of inhibitors protein-protein interactions. The company has now identified a new class of antimicrobial compounds with activity against clinically important antibiotic-resistant bacterial infections, and has technology to address modes of antibiotic action and development of resistance. To advance drug development, the Company pursues a hybrid business model of drug discovery and commercialization of its state-of-the-art technology platform.

The Need

The growth of life-threatening, antibiotic-resistant pathogens, especially the so-called ESKAPE pathogens, six pathogens “escaping” existing antibacterial drugs while representing the majority of all hospital infections, highlight the urgent need of new classes of antibiotics. MRSA infections cause a 35-fold increased risk of hospitalization, a seven-fold-increased risk of death, and at least $60,000 of additional hospital costs per patient, relative to uninfected controls. This is a serious disease with a death rate of 20% for invasive MRSA infections (USA data).

Market 1 – DRUGS

While the global antibiotics market generated $ 42 billion in 2009 representing 46% of anti-infective agent sales and 5% of the global pharmaceutical market, the smaller market of severe (nosocomial) infections caused by drug-resistant organisms is more tangible, offers higher drug prices and higher growth, and therefore is attractive. The global market of broad-spectrum antibiotics is dominated by three classes of antibiotics (in terms of sales), the cephalosporines (28%, $ 11,9 billion), the broad-spectrum penicillins (19%, $ 7,9 billion) and the fluoroquinolones (17%, $ 7,1 billion), and showed annual growth rates of 3.4- 5% between 2005 and 2009. Our focus, the Methicillin-resistant Staphylococcus aureus (MRSA) market stood at $1450 million in 2006, which then grew at a compound annual growth rate of 12.9% to reach $2660 million in 2011. The forecasts are that the market will grow to reach $3470 million by 2019

[1] Nature Reviews Drug Discovery 9, 675-676, 2010


The size of the market for all Life Science Tools & Reagents is huge with $42 billion in 2010, of which $5 billion were for protein-targeted reagents, such as PROCOMCURE’s, growing to this year to $8 billion [2]. There are many players in this market, known to all life science researchers, but these customers need a wide variety of sometimes specialized tools, some of which PROCOMCURE can offer because the scope of its protein-targeted reagents is not limited by the immune response, as with antibodies.

[2] BCC Research, Life Science Tools and Reagents: Global Markets, 2011

What we do

PROCOMCURE has promising lead-compounds of a new class of antibacterial agents with activity against methicillin-resistant Staphylococcus aureus (MRSA), and the company has proprietary tools for analysis of anti-bacterial modes of action. These tools originate from PROCOMCURE’s patented technology platform on protein-protein interactions and chemi-genomic resources. A collection of all Staphylococcus aureus genes, proteins & methods to express them, including a MRSA strain collection composed of >3000 strains each manipulated for a single S. aureus gene in a constitutive or inducible fashion. Furthermore PROCOMCURE produced in-house a systematic collection of recombinant proteins of 95% of all S. aureus essential genes, which allows Mode of Action studies or compound-resistance studies in a systematic and genome-wide manner of pharmaceutically interesting targets. Finally, huge in-house produced recombinant linear & cyclic peptide-, protein-, and antibody libraries and protein chips are combined with proprietary cell based and cell-free screening technologies. This technology platform is also the basis for technology-focused deals such as affinity reagents for purification & detection of biologic material and even future drug-candidates derived from protein-protein interaction inhibitors.